特发性炎症性肌病中简表-36的心理测量学特性:信度、效度与反应性
研究纳入105例特发性炎症性肌病患者,评估简表-36(SF-36)作为健康相关生活质量测量的信度、效度与反应性。结果显示SF-36各领域信度良好,与多数肌炎核心指标显著相关,躯体成分总结评分与2016年美国风湿病学会/欧洲抗风湿病联盟肌炎应答标准及医患整体变化评估呈显著一致变化且效应量大。作者结论认为SF-36信度、效度和反应性良好,应可用于临床实践和肌炎试验中的健康相关生活质量评估。
要点
- 特发性炎症性肌病患者SF-36各领域评分显著低于一般人群。
- SF-36各成分1个月重测信度良好(P<0.001)。
- 躯体成分总结评分变化与2016年美国风湿病学会/欧洲抗风湿病联盟肌炎应答标准及医患变化评估一致,效应量大。
核心结论
- SF-36在特发性炎症性肌病中显示良好的信度、效度和反应性,作者认为应将其用于临床实践和肌炎试验中的健康相关生活质量评估。
研究设计与样本
- 研究纳入符合欧洲抗风湿病联盟/美国风湿病学会分类标准或具有肌炎特异性抗体的特发性炎症性肌病患者,来自两项临床试验(托珠单抗治疗肌炎试验和阿巴西普治疗肌炎试验)和一项前瞻性观察性研究,共105例。
- 在0、3和6个月收集数据,包括所有肌炎核心指标(含手动肌力测试-8)以及SF-36总结评分和全部8个亚领域(含躯体成分总结评分和躯体功能)。
- 计算重测信度(Pearson相关)、效度(与其他有效测量的关联)和反应性(基于临床重要差异和效应量)。
主要发现
- 105例患者中44%为皮肌炎、30%为抗合成酶综合征、18%为多发性肌炎、8%为坏死性肌病,平均年龄52.3岁,64%为女性,85%为白人。
- 与一般人群相比,特发性炎症性肌病患者的健康相关生活质量评分显著降低。
- 活动性疾病和肌肉无力的患者所有SF-36领域评分均显著降低。
- 所有SF-36成分在1个月时重测信度良好(P<0.001),与大多数肌炎核心指标在基线和纵向均呈显著关联。
- 手动肌力测试-8的变化与躯体成分总结评分及躯体领域的变化强相关;躯体成分总结评分与2016年美国风湿病学会/欧洲抗风湿病联盟肌炎应答标准及医生/患者变化评估呈显著一致变化,效应量大;基于最小临床变化队列提出初步临床重要差异。
关键数值与推荐
- SF-36所有领域评分在活动性疾病患者和肌肉无力患者中均显著低于无上述情况者。
- SF-36所有成分1个月重测信度Pearson相关P<0.001。
- 躯体成分总结评分与2016年美国风湿病学会/欧洲抗风湿病联盟肌炎应答标准及医生/患者变化评估的一致变化效应量大。
临床怎么用
- 作者结论认为SF-36信度、效度和反应性良好,应将其用于临床实践和肌炎试验中评估健康相关生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the psychometric properties of Short Form-36 (SF-36) as a health-related quality of life (HRQoL) measure in idiopathic inflammatory myopathies (IIMs). METHODS: Patients fulfilling the EULAR/ACR classification criteria or with myositis-specific antibodies were enrolled from two clinical trials (Tocilizumab in Myositis and Abatacept in Myositis) and one prospective observational study. Data collection at 0, 3 and 6 months included all myositis core set measures (CSMs) including manual muscle testing-8 (MMT-8), and SF-36 summary scores and all eight subdomains including physical component summary score (PCS) and physical function. Test-retest reliability (Pearson correlation), validity (association with other valid measures) and responsiveness using clinically important difference (CID) and effect size were calculated. RESULTS: The study included 105 IIM patients (44% DM, 30% anti-synthetase syndrome, 18% PM, 8% necrotizing myopathy), with mean age: 52.3 years, 64% females and 85% White. HRQoL scores were significantly lower in IIM compared with the general population. All SF-36 domain scores were significantly lower in patients with active disease and muscle weakness. All SF-36 components demonstrated good test-retest reliability at 1 month (P < 0.001), with significant baseline and longitudinal associations with most myositis CSMs. Changes in MMT-8 strongly correlated with changes in PCS and physical domains. PCS illustrated significant and concordant change with 2016 ACR/EULAR myositis response criteria and physician/patient assessments of change, showing a large effect size. We present preliminary CIDs based on a cohort with minimal clinical change. CONCLUSION: SF-36 demonstrates good reliability, validity and responsiveness in IIM and should be utilized for assessing HRQoL in clinical practice and myositis trials.
引用
- Keret S, Aggarwal A, Almackenzie M, et al. Short Form-36 psychometric properties in idiopathic inflammatory myopathies: reliability, validity and responsiveness. Rheumatology (Oxford). 2025. PMID: 40279268. doi:10.1093/rheumatology/keaf219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。